Corcept therapeutics inc (CORT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities:
Net income

105,972

94,181

86,808

78,215

76,225

75,410

151,732

147,742

142,193

129,122

35,389

24,217

12,547

8,140

4,502

1,316

-1,597

-6,408

-11,262

-16,668

-22,283

-31,383

-38,612

-43,511

-47,857

-46,011

-46,011

-43,399

-39,098

-38,048

0

0

0

Adjustments to reconcile net income to net cash generated from operations:
Stock-based compensation

30,535

29,313

27,969

27,208

25,489

23,747

21,313

18,426

15,614

13,361

11,486

9,694

8,146

7,058

6,594

6,306

6,217

6,013

5,907

5,575

5,232

5,201

5,127

5,224

5,264

5,196

4,929

4,614

4,232

5,310

0

0

0

Accretion of interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,214

2,456

2,670

2,848

3,000

3,198

3,396

3,678

3,944

4,182

4,339

4,410

0

0

0

-

-

-

-

Depreciation and amortization of property and equipment

-

-

-

-

-

-

-

-

-

14

19

21

21

21

18

22

21

22

26

26

27

29

31

30

32

35

0

0

0

-

-

-

-

Deferred income taxes

21,046

16,877

15,196

14,259

11,824

14,067

-66,101

-71,061

-73,534

-76,703

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of interest income

-2,195

-1,738

-1,328

-1,214

-889

-1,721

1,020

583

-12

456

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization of property and equipment

845

703

547

394

284

236

211

189

141

106

73

58

73

87

100

109

142

155

164

173

153

141

125

106

88

74

66

52

38

27

0

0

0

Non-cash amortization of right-of-use asset

1,419

1,468

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Trade receivables

7,466

2,340

3,045

-8,930

1,957

2,288

7,488

19,200

8,047

5,440

3,636

203

2,462

3,639

2,291

4,350

2,451

2,887

3,199

2,726

2,379

1,906

1,727

1,370

779

871

0

0

0

-

-

-

-

Other receivable

-

-

-

-

-

-12,896

-12,965

0

20

12,896

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

626

1,044

4,087

7,251

7,459

7,779

6,264

3,198

128

2,262

201

2,205

2,516

682

713

-777

-848

-815

-914

-769

-417

-249

-47

96

781

883

3,078

3,107

4,620

4,663

0

0

0

Prepaid expenses and other current assets

-48

-1,696

3,523

2,623

2,437

5,071

1,189

1,052

1,505

705

1,765

1,101

693

1,322

141

185

484

-799

-589

-925

-831

531

765

1,365

881

290

204

193

470

480

0

0

0

Other assets

3,366

3,398

97

97

2

0

29

4

24

26

0

25

25

0

-4

-1

-3

7

10

10

9

-10

-8

-11

-8

4

-5

-236

-48

-11

0

0

0

Accounts payable

-4,288

-735

-8,156

526

1,323

-389

7,710

4,291

3,567

6,289

1,903

-7

2,171

965

2,569

-279

1,046

-561

-220

-235

-2,630

-495

-377

-438

1,403

-1,423

763

-1,202

179

193

0

0

0

Accrued clinical expenses

3,401

2,956

-1,271

321

1,051

1,274

3,500

3,886

2,025

780

117

548

367

296

1,166

471

-264

835

333

-1,151

-2,022

-2,952

-1,687

599

2,797

2,445

1,358

404

-198

199

0

0

0

Accrued and other liabilities

763

-517

688

-2,675

2,471

5,044

3,396

5,643

5,178

8,546

9,378

6,393

5,411

5,696

4,042

3,326

2,108

1,381

1,293

883

1,148

575

252

309

-150

255

0

0

0

-

-

-

-

Operating lease liabilities

-1,444

-1,452

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-158

-79

-37

-55

125

29

-7

26

8

-5

7

-47

9

0

0

0

-

-

-

-

Accrued compensation and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash provided by operating activities

145,705

136,117

109,182

115,260

104,916

115,665

119,029

85,449

85,804

60,935

40,621

38,631

24,655

18,391

17,985

9,933

8,204

3,130

-2,436

-9,248

-18,093

-27,376

-33,639

-36,312

-36,564

-37,058

-38,134

-38,761

-37,417

-36,020

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

873

1,088

1,066

825

478

298

214

251

386

419

465

473

282

194

102

12

5

17

34

50

98

174

214

263

219

127

145

132

162

151

0

0

0

Proceeds from maturities of marketable securities

179,715

182,295

222,600

232,500

196,830

142,655

105,976

68,450

46,600

29,950

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

276,569

299,035

279,130

268,461

253,193

233,124

222,220

162,798

134,550

102,987

58,092

35,853

19,303

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-97,727

-117,828

-57,596

-36,786

-56,841

-90,767

-116,458

-94,599

-88,336

-73,456

-46,083

-34,526

-19,585

-194

-102

-12

-5

-17

-34

-50

-98

-174

-214

-263

-219

-127

-145

-132

-162

-151

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of options, net of issuance costs

6,464

8,419

9,365

7,303

9,835

9,322

9,167

11,305

7,979

7,181

8,224

6,719

8,732

7,683

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

59,419

0

0

0

Repurchase of common stock

17,695

30,975

45,728

54,632

37,212

23,657

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments related to debt obligation

-

-

-

-

-

-

-

-

-

15,134

19,567

18,990

16,570

14,779

13,110

11,564

10,383

9,207

8,011

6,797

5,726

4,856

0

0

0

-

-

-

-

-

-

-

-

Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercise

1,920

6,089

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-13,151

-28,645

-40,532

-51,498

-31,546

-14,335

263

6,692

-2,323

-7,953

-11,343

-12,271

-7,838

-7,096

-6,468

-5,180

-5,408

13,074

12,140

12,372

12,526

-3,079

0

0

0

-

-

-

-

89,568

0

0

0

Supplemental disclosure:
Net increase in cash and cash equivalents

34,827

-10,356

11,054

26,976

16,529

10,563

2,834

-2,458

-4,855

-20,474

-16,805

-8,166

-2,768

11,101

11,415

4,741

2,791

16,187

9,670

3,074

-5,665

-30,629

-36,395

-38,246

-37,842

-38,155

-38,453

37,321

38,833

53,397

0

0

0

Supplemental disclosure:
Exercise price of shares tendered in net settlement of cashless option exercise

1,052

1,983

931

931

931

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recognition of right-of-use asset and lease liability

3,035

4,913

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-